Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Sep

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

FDA Approves Belzutifan in Combination With Lenvatinib for Advanced ccRCC

FDA Advisory Committee Votes In Favor of Approval of Multi-Cancer Early Detection Test

New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast Cancer

CAP Updates Cancer Protocols for Breast Cancer Biomarker Reporting and GIST Molecular Testing

Robert Kyle Myeloma Expert Dies at 98